dc.contributor.author |
Pitakchotiwan P. |
|
dc.contributor.author |
Linasmita P. |
|
dc.contributor.author |
Buppanharun J. |
|
dc.contributor.author |
Upapan P. |
|
dc.contributor.author |
Wanthong N. |
|
dc.contributor.author |
Tantisiriwat W. |
|
dc.date.accessioned |
2022-03-10T13:17:39Z |
|
dc.date.available |
2022-03-10T13:17:39Z |
|
dc.date.issued |
2021 |
|
dc.identifier.issn |
1252208 |
|
dc.identifier.other |
2-s2.0-85117166101 |
|
dc.identifier.uri |
https://ir.swu.ac.th/jspui/handle/123456789/17577 |
|
dc.identifier.uri |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85117166101&doi=10.35755%2fjmedassocthai.2021.10.13128&partnerID=40&md5=3aeef7a75cf8113598817e0d77dfcf2e |
|
dc.description.abstract |
Background: Recently, the authors had reported a case with abacavir hypersensitivity reaction (ABC-HSR), the first diagnosed patient at the HRH Princess Maha Chakri Sirindhorn Medical Center (MSMC). There was no data regarding the incidence or prevalence of ABC-HSR previously reported in Thailand. Objective: To study the prevalence of ABC-HSR, the abacavir use pattern and the cost effectiveness for the routine human leukocyte antigen (HLA)-B*5701 screening before abacavir use by analyses of the MSMC data. Materials and Methods: All patients at the MSMC who were prescribed abacavir from October 1, 2010 to September 30, 2020 were retrospectively reviewed for ABC-HSR and the abacavir use pattern at the time when abacavir was started. The cost-effectiveness analysis was applied by analyzing the cost between the routine HLA-B*5701 screening before abacavir use and the HLA-B*5701 confirmation for ABC-HSR. The cost for the prevention of a case of ABC-HSR was defined. Results: There were total of 54 patients who were prescribed abacavir and only one ABC-HSR case diagnosed. The prevalence of ABC-HSR was 1.85%. The main reason for the abacavir prescription was a substitution for tenofovir (TDF) because of the TDF adverse effects (81.13%). The HLA-B*5701 screening before abacavir use was done in 26.42% at the MSMC. If all eligible patients were routinely screened for the HLA-B*5701 allele before abacavir use, the cost would be 54,000 Baht. The cost for the diagnosis and the management of the ABC- HSR case was 7,230 Baht. The cost for the prevention of a case of ABC-HSR was 46,770 Baht. Conclusion: The prevalence of ABC-HSR was low. The main reason for abacavir use was a substitution for TDF. The cost for the prevention for a case of ABC-HSR was 46,770 Baht which would be less if the cost for the HLA-B*5701 test was reduced. © JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND | 2021. |
|
dc.language |
en |
|
dc.subject |
abacavir |
|
dc.subject |
HLA B57 antigen |
|
dc.subject |
tenofovir |
|
dc.subject |
abdominal pain |
|
dc.subject |
allele |
|
dc.subject |
allergic reaction |
|
dc.subject |
Article |
|
dc.subject |
CD4 lymphocyte count |
|
dc.subject |
cost effectiveness analysis |
|
dc.subject |
drug efficacy |
|
dc.subject |
gene frequency |
|
dc.subject |
genotype |
|
dc.subject |
human |
|
dc.subject |
Human immunodeficiency virus infection |
|
dc.subject |
hyperlipidemia |
|
dc.subject |
hypersensitivity |
|
dc.subject |
kidney failure |
|
dc.subject |
liver toxicity |
|
dc.subject |
lymphocytopenia |
|
dc.subject |
myalgia |
|
dc.subject |
nephrotoxicity |
|
dc.subject |
pharyngitis |
|
dc.subject |
prescription |
|
dc.subject |
prevalence |
|
dc.subject |
root cause analysis |
|
dc.subject |
spirometry |
|
dc.subject |
substitution reaction |
|
dc.subject |
sustained virologic response |
|
dc.subject |
thorax radiography |
|
dc.subject |
virus load |
|
dc.title |
Prevalence of abacavir hypersensitivity reaction and cost-effectiveness of hla b*5701 screening: A ten-year experience in the hrh princess maha chakri sirindhorn medical center |
|
dc.type |
Article |
|
dc.rights.holder |
Scopus |
|
dc.identifier.bibliograpycitation |
Journal of the Medical Association of Thailand. Vol 104, No.10 (2021) |
|
dc.identifier.doi |
10.35755/jmedassocthai.2021.10.13128 |
|